Shares of Zealand Pharma A/S – American Depositary Shares (NASDAQ:ZEAL) have received an average broker rating score of 1.83 (Buy) from the three brokers that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company.

Brokers have set a 1-year consensus price target of $27.33 for the company and are predicting that the company will post ($0.49) EPS for the current quarter, according to Zacks. Zacks has also assigned Zealand Pharma A/S – American Depositary Shares an industry rank of 193 out of 265 based on the ratings given to its competitors.

Several brokerages have recently commented on ZEAL. Needham & Company LLC restated a “buy” rating and set a $26.00 price target on shares of Zealand Pharma A/S – American Depositary Shares in a research note on Monday, October 16th. Zacks Investment Research lowered Zealand Pharma A/S – American Depositary Shares from a “buy” rating to a “hold” rating in a research note on Saturday, January 13th.

A number of hedge funds have recently modified their holdings of ZEAL. Royce & Associates LP bought a new stake in Zealand Pharma A/S – American Depositary Shares during the third quarter valued at about $1,152,000. Jane Street Group LLC bought a new stake in Zealand Pharma A/S – American Depositary Shares during the third quarter valued at about $386,000. Finally, Susquehanna International Group LLP bought a new stake in Zealand Pharma A/S – American Depositary Shares during the third quarter valued at about $3,185,000. 13.33% of the stock is currently owned by institutional investors.

Shares of Zealand Pharma A/S – American Depositary Shares (NASDAQ ZEAL) traded up $0.32 during trading on Wednesday, hitting $15.28. The stock had a trading volume of 36,986 shares, compared to its average volume of 23,337. Zealand Pharma A/S – American Depositary Shares has a 1 year low of $12.45 and a 1 year high of $20.37.

Zealand Pharma A/S – American Depositary Shares (NASDAQ:ZEAL) last announced its quarterly earnings results on Wednesday, November 8th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.13. analysts forecast that Zealand Pharma A/S – American Depositary Shares will post -1.46 EPS for the current year.

TRADEMARK VIOLATION WARNING: This news story was first published by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another site, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this news story can be read at https://www.dailypolitical.com/2018/02/10/1755472.html.

About Zealand Pharma A/S – American Depositary Shares

Zealand Pharma A/S, a biotech company, engages in the discovery, design, and development of novel peptide-based medicines in Denmark. The company markets Lixisenatide, a once-daily prandial GLP-1 peptide receptor agonist for the treatment of type 2 diabetes under the Adlyxin and Lyxumia names; and Soliqua 100/33/Suliqua, a combination of lixisenatide and insulin glargine, and a GLP-1 receptor agonist for the treatment of type 2 diabetes.

Get a free copy of the Zacks research report on Zealand Pharma A/S – American Depositary Shares (ZEAL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Zealand Pharma A/S - American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S - American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.